India's GDP growth is projected to spike to a four-quarter high of 13 per cent in Q1 (April-June) FY23 due to a low base of Covid 2.0 and robust recovery in contact-intensive services, according to ICRA.
Hyderabad-based Bharat Biotech has submitted data from Phase 3 clinical trials of BBV154, its intranasal Covid vaccine candidate, to the drug regulator.
EXAMIANS